PCC ROKITA SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.2 PLN | +1.19% |
|
+1.79% | +6.57% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the best yield companies with high dividend expectations.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.89 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +6.57% | 504M | - | ||
| +11.76% | 63.38B | A- | ||
| -3.51% | 46.51B | A- | ||
| +13.09% | 39.91B | B+ | ||
| +19.43% | 25.57B | A- | ||
| +8.37% | 18.95B | C+ | ||
| +1.44% | 17.58B | B+ | ||
| -20.33% | 16.1B | A- | ||
| +0.36% | 14.98B | B+ | ||
| -12.98% | 14.78B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PCR Stock
- Ratings PCC Rokita SA
